GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » E10

Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) E10 : $-1.31 (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Arrowhead Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $-1.240. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.31 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average E10 Growth Rate was -6.50% per year. During the past 5 years, the average E10 Growth Rate was 2.50% per year. During the past 10 years, the average E10 Growth Rate was 14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Arrowhead Pharmaceuticals was 32.40% per year. The lowest was -6.50% per year. And the median was 20.20% per year.

As of today (2024-04-26), Arrowhead Pharmaceuticals's current stock price is $22.155. Arrowhead Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $-1.31. Arrowhead Pharmaceuticals's Shiller PE Ratio of today is .


Arrowhead Pharmaceuticals E10 Historical Data

The historical data trend for Arrowhead Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals E10 Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 -1.01 -1.15 -1.17 -1.22

Arrowhead Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.17 -1.09 -1.17 -1.22 -1.31

Competitive Comparison of Arrowhead Pharmaceuticals's E10

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Shiller PE Ratio falls into.



Arrowhead Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arrowhead Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.24/129.4194*129.4194
=-1.240

Current CPI (Dec. 2023) = 129.4194.

Arrowhead Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201403 -0.310 99.695 -0.402
201406 -0.220 100.560 -0.283
201409 -0.440 100.428 -0.567
201412 -0.410 99.070 -0.536
201503 -0.510 99.621 -0.663
201506 -0.270 100.684 -0.347
201509 -0.410 100.392 -0.529
201512 -0.320 99.792 -0.415
201603 -0.350 100.470 -0.451
201606 -0.320 101.688 -0.407
201609 -0.340 101.861 -0.432
201612 -0.170 101.863 -0.216
201703 -0.080 102.862 -0.101
201706 -0.070 103.349 -0.088
201709 -0.150 104.136 -0.186
201712 -0.180 104.011 -0.224
201803 -0.180 105.290 -0.221
201806 -0.180 106.317 -0.219
201809 -0.120 106.507 -0.146
201812 0.130 105.998 0.159
201903 0.240 107.251 0.290
201906 0.210 108.070 0.251
201909 0.110 108.329 0.131
201912 -0.030 108.420 -0.036
202003 -0.200 108.902 -0.238
202006 -0.130 108.767 -0.155
202009 -0.480 109.815 -0.566
202012 -0.200 109.897 -0.236
202103 -0.260 111.754 -0.301
202106 -0.290 114.631 -0.327
202109 -0.610 115.734 -0.682
202112 -0.600 117.630 -0.660
202203 0.410 121.301 0.437
202206 -0.680 125.017 -0.704
202209 -0.810 125.227 -0.837
202212 -0.390 125.222 -0.403
202303 0.450 127.348 0.457
202306 -0.960 128.729 -0.965
202309 -1.020 129.860 -1.017
202312 -1.240 129.419 -1.240

Add all the adjusted EPS together and divide 10 will get our e10.


Arrowhead Pharmaceuticals  (NAS:ARWR) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Arrowhead Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Executives
James C Hamilton other: Senior Vice President 177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Mauro Ferrari director 201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Tracie Oliver officer: Chief Commercial Officer 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Patrick O'brien officer: General Counsel 225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San officer: Chief Medical Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Kenneth Allen Myszkowski officer: CFO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone director, officer: President and CEO ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry director C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105